Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inflammatory marker assessment in ulcerative colitis patients treated with tofacitinib
NL-OMON40572Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tofacitinib in autoimmune colitis (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Inflammatory infiltrate, Transcription of inflammatory genes and 1 more. Started Nov 2013; status: active, not recruiting.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON40572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40572.